Provided by Tiger Trade Technology Pte. Ltd.

C4 Therapeutics, Inc.

3.09
+0.14004.75%
Pre-market: 3.07-0.0200-0.65%08:13 EST
Volume:3.22M
Turnover:9.90M
Market Cap:301.52M
PE:-2.28
High:3.20
Open:2.95
Low:2.91
Close:2.95
52wk High:3.65
52wk Low:1.09
Shares:97.58M
Float Shares:72.05M
Volume Ratio:0.62
T/O Rate:4.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3568
EPS(LYR):-1.2666
ROE:-44.44%
ROA:-18.43%
PB:1.18
PE(LYR):-2.44

Loading ...

C4 Therapeutics Raises $125 Million and Reports Positive Phase 1 Cemsidomide Data

Reuters
·
Nov 06, 2025

C4 Therapeutics: Expects Current Cash, Cash Equivalents & Marketable Securities Will Enable Co to Fund Its Operating Plan to End of 2028

THOMSON REUTERS
·
Nov 06, 2025

C4 Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
Oct 31, 2025

C4 Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
Oct 27, 2025

Point72 Asset Management Lp Reports 9.9% Passive Stake in C4 Therapeutics as of Oct 17 - SEC Filing

THOMSON REUTERS
·
Oct 21, 2025

C4 Therapeutics prices $125M underwritten offering

TIPRANKS
·
Oct 16, 2025

C4 Therapeutics Announces $125 Million Underwritten Offering with Potential to Raise Up to $349.7 Million Through Stock and Warrant Sales

Reuters
·
Oct 16, 2025

C4 Therapeutics Inc - Proceeds Could Reach $349.7 Mln IF All Warrants Exercised

THOMSON REUTERS
·
Oct 16, 2025

Press Release: C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

Dow Jones
·
Oct 16, 2025

C4 Therapeutics Presents Phase 1 Trial Data

TIPRANKS
·
Oct 16, 2025

C4 Therapeutics Showcases Pipeline Progress and Highlights Potential of Cemsidomide and Next-Generation Degrader Programs

Reuters
·
Oct 01, 2025

BUZZ-C4 Therapeutics climbs after partnership with Pfizer for cancer therapy trial

Reuters
·
Oct 01, 2025

C4 Therapeutics announces trial collab, supply agreement with Pfizer

TIPRANKS
·
Oct 01, 2025

C4 Therapeutics Announces Clinical Trial Collaboration with Pfizer to Combine Cemsidomide and Elranatamab for Multiple Myeloma Treatment

Reuters
·
Oct 01, 2025

C4 Therapeutics Inc - Pfizer to Supply Elranatamab at No Cost; C4t to Conduct Trial

THOMSON REUTERS
·
Oct 01, 2025

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement With Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Oct 01, 2025

CCCC Lisbon 2025 Announces Bybit EU and Top Partners as Sponsors of Its Third Global Edition

prnewswire
·
Sep 29, 2025

C4 Therapeutics Announces Promising Phase 1 Trial Results for Cemsidomide in Relapsed/Refractory Multiple Myeloma Treatment

Reuters
·
Sep 23, 2025

C4 Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Sep 23, 2025

C4 Therapeutics Price Target Maintained With a $6.00/Share by Stephens & Co.

Dow Jones
·
Sep 22, 2025